ATE546526T1 - Hybrid-interferenz-rna - Google Patents

Hybrid-interferenz-rna

Info

Publication number
ATE546526T1
ATE546526T1 AT06743972T AT06743972T ATE546526T1 AT E546526 T1 ATE546526 T1 AT E546526T1 AT 06743972 T AT06743972 T AT 06743972T AT 06743972 T AT06743972 T AT 06743972T AT E546526 T1 ATE546526 T1 AT E546526T1
Authority
AT
Austria
Prior art keywords
interference rna
hybrid interference
hybrid
rna
molecule
Prior art date
Application number
AT06743972T
Other languages
English (en)
Inventor
Josephine Anne Milner
Michael Gait
Ming Jiang
Andrei Arzumanov
Original Assignee
Univ York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0510612A external-priority patent/GB0510612D0/en
Priority claimed from GB0510617A external-priority patent/GB0510617D0/en
Priority claimed from GB0516191A external-priority patent/GB0516191D0/en
Priority claimed from GB0516193A external-priority patent/GB0516193D0/en
Application filed by Univ York filed Critical Univ York
Application granted granted Critical
Publication of ATE546526T1 publication Critical patent/ATE546526T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT06743972T 2005-05-25 2006-05-24 Hybrid-interferenz-rna ATE546526T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0510612A GB0510612D0 (en) 2005-05-25 2005-05-25 Polymerase chain reaction
GB0510617A GB0510617D0 (en) 2005-05-25 2005-05-25 Hybrid interfering RNA
GB0516191A GB0516191D0 (en) 2005-08-06 2005-08-06 Polymerase chain reaction
GB0516193A GB0516193D0 (en) 2005-08-06 2005-08-06 Hybrid interfering rna
PCT/GB2006/001895 WO2006125977A2 (en) 2005-05-25 2006-05-24 Hybrid interfering rna

Publications (1)

Publication Number Publication Date
ATE546526T1 true ATE546526T1 (de) 2012-03-15

Family

ID=37420934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06743972T ATE546526T1 (de) 2005-05-25 2006-05-24 Hybrid-interferenz-rna

Country Status (4)

Country Link
US (2) US8067572B2 (de)
EP (1) EP1891216B1 (de)
AT (1) ATE546526T1 (de)
WO (1) WO2006125977A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1304768B1 (it) * 1998-10-05 2001-03-29 Esaote Spa Lettino porta paziente o simili, e macchina, in particolare macchinaper il rilevamento d'immagini in risonanza magnetica nucleare in
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
GB0716072D0 (en) * 2007-08-17 2007-09-26 Univ York Therapy
AU2009279458B2 (en) * 2008-08-08 2015-07-02 Code Biotherapeutics, Inc. Long-acting DNA dendrimers and methods thereof
KR20110110776A (ko) * 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
WO2011132672A1 (ja) * 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
US20110306653A1 (en) 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
EP3269811B1 (de) * 2010-07-28 2020-10-07 Advanced Innovation Development Co. Ltd. Nukleinsäure mit adjuvans-aktivität und deren verwendung
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
CN103328633B (zh) 2010-10-22 2018-07-10 成均馆大学校产学协力团 诱导rna干扰的核酸分子及其用途
JPWO2013058306A1 (ja) * 2011-10-19 2015-04-02 独立行政法人理化学研究所 機能性核酸の特異的修飾による活性化
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
CN108148838B (zh) 2012-05-22 2026-07-31 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
JP6346265B2 (ja) 2013-03-21 2018-06-20 ジェニスフィア・エルエルシー Dnaインターカレーティング剤の細胞送達
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
KR20180095511A (ko) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
JP7027311B2 (ja) 2015-11-16 2022-03-01 オリックス ファーマシューティカルズ,インコーポレーテッド MyD88又はTLR3を標的とするRNA複合体を使用した加齢黄斑変性の治療
KR102825945B1 (ko) 2016-02-02 2025-06-30 올릭스 주식회사 Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
WO2017134525A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
WO2017143156A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
JP7049262B2 (ja) 2016-04-11 2022-04-06 オリックス ファーマシューティカルズ,インコーポレーテッド 結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
AU2018251788B2 (en) 2017-04-12 2025-04-10 Aura Biosciences, Inc. Targeted combination therapy
JP7535047B2 (ja) * 2018-12-12 2024-08-15 ディセルナ ファーマシューティカルズ インコーポレイテッド トリループを含む二本鎖核酸インヒビター分子
CN114072503A (zh) * 2019-07-02 2022-02-18 阿尔戈诺特Rna有限公司 载脂蛋白b拮抗剂
CN110269014B (zh) * 2019-07-23 2021-01-12 中国海洋大学 一种单环刺螠幼虫的rna干扰方法
US20230183694A1 (en) * 2020-03-16 2023-06-15 Argonaute RNA Limited Antagonist of pcsk9
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
WO2022166849A1 (en) * 2021-02-08 2022-08-11 Ractigen Therapeutics Multi-valent oligonucleotide agent and methods of use thereof
US20250283076A1 (en) * 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー,アン,ジョセフィーヌ 遺伝子発現のサイレンシング
US20030194718A1 (en) * 2002-04-15 2003-10-16 Hitachi. Ltd. Probing sequence determination system for DNA arrays
CA2505603A1 (en) * 2002-11-18 2004-06-03 Genospectra, Inc. Caged sensors, regulators and compounds and uses thereof
JP2004261002A (ja) * 2003-01-08 2004-09-24 Tsutomu Suzuki siRNAの製造方法
US7407784B2 (en) * 2003-01-20 2008-08-05 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. L-amino acid oxidase with cytotoxic activity from Aplysia punctata
WO2006078798A2 (en) 2005-01-18 2006-07-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RETINOBLASTOMA (RB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA

Also Published As

Publication number Publication date
WO2006125977A2 (en) 2006-11-30
EP1891216A2 (de) 2008-02-27
EP1891216B1 (de) 2012-02-22
US20090012022A1 (en) 2009-01-08
US8067572B2 (en) 2011-11-29
WO2006125977A3 (en) 2007-01-25
US20120136040A1 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
WO2006125977A3 (en) Hybrid interfering rna
BRPI0819193A2 (pt) uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
MX2008008261A (es) Intercambio nucleotidico dirigido mejorado con oligonucleotidos modificados por lna.
EP1731525A4 (de) Nukleotidderivate und dna-mikroarray
DK1713912T3 (da) Modificerede Korte Interfererende RNA (Modificerede siRNA)
EP2294195A4 (de) Oligonukleotid-duplexe mit dna-ähnlichen und rna-ähnlichen nukleotiden und verwendungen dafür
EP2089517A4 (de) Polymeraseenzyme und reagenzien für erweiterte nukeinsäuresequenzierung
EP1723162A4 (de) Anti-mikrorna-oligonukleotidmoleküle
EP2064223A4 (de) Duplexoligonukleotide und verfahren zum gen-silencing durch rna-interferenz
EP1646639B8 (de) Nucleotid-phosphoramidate als antikrebs- verbindungen
PL1807520T3 (pl) Konstrukty do RNA
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
ATE502122T1 (de) Chemisch modifizierte oligonukleotidprimer zur nukleinsäureamplifikation
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2008087641A3 (en) H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2005049832A3 (en) FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2008016906A3 (en) 3'-phosphate-labeled nucleotide analogs and their use for sequencing a nucleic acid
DE602005027253D1 (de) Herbizidresistenz verleihende gene
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
ATE407939T1 (de) 2ß-NITROBENZYL-MODIFIZIERTE RIBONUKLEOTIDE
EP2157182A3 (de) Modifizierte kurz interferierende RNA
IL197415A0 (en) Azole nucleosides and use as inhibitors of rna and dna varial polymerases
GB0621361D0 (en) Use of DNA polymerases
WO2007084359A3 (en) Compositions and methods for the treatment of influenza infection
IL189540A0 (en) Chemically modified short interfering nucleic acid molecules that mediate rna interference